Neoplasms

All Conditions

Rare Diseases

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Temozolomide

Antineoplastic Agents, Alkylating

Alkylating Agents

Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide

Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.

partial brain irradiation

will be assessed for tumor type and tumor markers

stereotactic biopsy of brain tumor

craniotomy and tumor resection

Lawrence Berk, MD, PhD

Trial to determine the safety of neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.

Prior to any definitive treatment and after enrollment, the patient will undergo stereotactic biopsy of the lesion to confirm the histology of the lesion and to determine methylated methylguanine methyltransferase (MGMT) status. Standard image-guided stereotactic technique will be used. Patients will be treated with conformal radiation therapy. Temozolomide will be given from the day prior to radiation therapy through the last day of radiation therapy. 4-6 weeks after radiation therapy the patient will undergo craniotomy and maximal safe resection. Temozolomide will continue beginning 4 weeks after surgery.

Imaging:

MRI within 2 weeks prior to the start of the protocol. MRI at 4 weeks after chemoradiation therapy and prior to surgery. MRI within 48 hours after surgery.

MRI after every 2 cycles of chemotherapy and then every 2 months until progression, up to 2 years.

Preoperative Chemoradiation for Glioblastoma

Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma

comparison of toxicity related to experimental treatment to historical local controls

determination of the feasibility of using standard MGMT activity measurement techniques on stereotactic specimens and comparison of the results with the results from the full resection.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Preoperative Chemoradiation for Glioblastoma	NCT02092038	Glioblastoma	Temozolomide partial brain i... stereotactic bi... craniotomy and ...	18 Years - 80 Years	Tampa General Hospital
Preoperative Chemoradiation for Glioblastoma	NCT02092038	Glioblastoma	Temozolomide partial brain i... stereotactic bi... craniotomy and ...	18 Years - 80 Years	Tampa General Hospital
Preoperative Chemoradiation for Glioblastoma	NCT02092038	Glioblastoma	Temozolomide partial brain i... stereotactic bi... craniotomy and ...	18 Years - 80 Years	Tampa General Hospital

Spots Global Cancer Trial Database for stereotactic biopsy of brain tumor